Relay Therapeutics (RLAY) Common Equity (2019 - 2026)

Relay Therapeutics (RLAY) has reported Common Equity for 8 consecutive years, with $642.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity fell 10.94% year-over-year to $642.2 million; the TTM figure through Mar 2026 stood at $642.2 million (down 10.94% YoY), while the FY2025 annual figure was $567.1 million, down 27.09% from the prior year.
• Common Equity improved to $642.2 million in Q1 2026 per RLAY's latest filing, from $567.1 million in the prior quarter.
• Across five years, Common Equity topped out at $999.8 million in Q3 2022 and bottomed at $567.1 million in Q4 2025.
• Historically, Common Equity has averaged $767.3 million across 5 years, with a median of $777.8 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity soared 75.06% — and 2025, when it retreated 27.56%.
• Relay Therapeutics' Common Equity stood at $950.2 million in 2022, then dropped by 20.86% to $752.0 million in 2023, then grew by 3.43% to $777.8 million in 2024, then decreased by 27.09% to $567.1 million in 2025, then grew by 13.25% to $642.2 million in 2026.
• Business Quant data shows RLAY's Common Equity at $642.2 million in Q1 2026, $567.1 million in Q4 2025, and $607.7 million in Q3 2025.